Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocation details rather than corporate financial performance.
Material Changes
On December 31, 2015, Non-Executive Directors were allocated notional Ordinary Shares and American Depositary Shares (ADSs) for the service period of October 1, 2015, to December 31, 2015. Additionally, Mr. Banga received a separate allocation for the period of September 1, 2015, to September 30, 2015. These allocations were formally notified to the Company and Directors on January 4, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share interests in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Allocation Date: Notional shares were allocated on December 31, 2015, and notified on January 4, 2016.
- Share Prices: Ordinary Shares were allocated at £13.83 per share (with a specific allocation to Mr. Banga at £12.51), and ADSs at $40.98 per ADS.
- Beneficiaries: Allocations were made to Non-Executive Directors including Sir Philip Hampton, Professor Sir Roy Anderson, Vindi Banga, Dr Stephanie Burns, Stacey Cartwright, Lynn Elsenhans, Judy Lewent, Sir Deryck Maughan, Dr Daniel Podolsky, Urs Rohner, and Hans Wijers.
- Specific Allocation: Mr. Banga received an additional 566.213 notional Ordinary Shares for a prior service period.